With the FDA nod, Lumryz becomes the only FDA-approved once-at-bedtime oxybate treatment for cataplexy and EDS in this patient population
Neither route has been validated in a completed human clinical trial, so both carry significant uncertainty
There are many possible causes and risk factors, primary ITP, an autoimmune condition the use of certain drugs some viral, bacterial, and other infections pregnancy a high alcohol consumption Thrombocytopenia, or a low platelet count, can happen for many reasons
For shoppers who want a cleaner, more advanced addition to a cutting or recomposition stack, this is one of the most talked about options in the category
Despite this, its biological effects on gene expression and telomerase activation persist for extended periods, suggesting a hit-and-run mechanism where transient peptide exposure triggers sustained downstream signaling
I remain curious, but cautious